Aliskiren is a direct renin inhibitor with favorable pharmacokinetic properties, but its clinical utility and safety, especially in combination with other RAAS inhibitors, require further clarification.
No takes yet. Share an insight, caveat, or question.
Aliskiren's profile merits targeted trials; leaves open safety with ACEi/ARBs and via (pro)renin receptors.
Ichihara et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: